MX350929B - Formulaciones peptidicas robustas de liberación controlada. - Google Patents
Formulaciones peptidicas robustas de liberación controlada.Info
- Publication number
- MX350929B MX350929B MX2014006624A MX2014006624A MX350929B MX 350929 B MX350929 B MX 350929B MX 2014006624 A MX2014006624 A MX 2014006624A MX 2014006624 A MX2014006624 A MX 2014006624A MX 350929 B MX350929 B MX 350929B
- Authority
- MX
- Mexico
- Prior art keywords
- low viscosity
- compositions
- forming
- acyl
- chains
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
Abstract
La presente invención se refiere a composiciones que forman una mezcla de baja viscosidad de: a. el 25 al 50% en peso de al menos un diacilglicerol y/o al menos un tocoferol; b. el 25 al 55% en peso de la menos un componente fosfolípido que comprende fosfolípidos que tienen i. grupos de cabeza polar que comprenden más del 50% de fosfatidiletanolamina y ii. Dos cadenas de acilo, cada una de las cuales posee independientemente de 16 a 20 carbonos, donde al menos una cadena de acilo tiene al menos una insaturación en la cadena de carbono, y donde hay no más de cuatro insaturaciones en las dos cadenas de carbono; c. el 5 al 25% en peso de al menos un solvente biocompatible, orgánico, de baja viscosidad que contiene oxígeno; donde del 0,1 al 10% en peso de al menos un agente peptídico activo que comprende al menos un agente peptídico activo que comprende al menos un agonista del receptor de somatostatina está disuelto o disperso en la mezcla de baja viscosidad; y donde la preformulación forma, o tiene la capacidad de formar, al menos una estructura de fase cristalina líquida no laminar al entrar en contacto con un fluido acuoso. La invención se relaciona adicionalmente con métodos de tratamiento que comprenden la administración de tales composiciones y con dispositivos de administración precargados y kits que contienen las formulaciones.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161566851P | 2011-12-05 | 2011-12-05 | |
PCT/EP2012/073841 WO2013083459A1 (en) | 2011-12-05 | 2012-11-28 | Robust controlled-release peptide formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014006624A MX2014006624A (es) | 2014-09-22 |
MX350929B true MX350929B (es) | 2017-09-26 |
Family
ID=47226199
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014006624A MX350929B (es) | 2011-12-05 | 2012-11-28 | Formulaciones peptidicas robustas de liberación controlada. |
MX2014006625A MX352024B (es) | 2011-12-05 | 2012-11-28 | Formulaciones potentes de liberacion controlada. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014006625A MX352024B (es) | 2011-12-05 | 2012-11-28 | Formulaciones potentes de liberacion controlada. |
Country Status (23)
Country | Link |
---|---|
US (2) | US9585959B2 (es) |
EP (2) | EP2787974B1 (es) |
JP (2) | JP6081480B2 (es) |
KR (2) | KR20140105527A (es) |
CN (2) | CN104093399B (es) |
AU (2) | AU2012348640B2 (es) |
BR (2) | BR112014013691A2 (es) |
CA (2) | CA2858227C (es) |
CL (1) | CL2014001472A1 (es) |
CO (1) | CO7000746A2 (es) |
DK (2) | DK2787975T3 (es) |
EA (2) | EA027924B1 (es) |
ES (2) | ES2629188T3 (es) |
HK (2) | HK1201722A1 (es) |
HR (1) | HRP20170954T1 (es) |
IL (2) | IL232789B (es) |
MX (2) | MX350929B (es) |
PE (1) | PE20141297A1 (es) |
PL (1) | PL2787975T3 (es) |
SG (1) | SG11201402673YA (es) |
SI (1) | SI2787974T1 (es) |
WO (2) | WO2013083459A1 (es) |
ZA (1) | ZA201403793B (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5127449B2 (ja) * | 2004-06-04 | 2013-01-23 | カムルス エービー | 流体デポ製剤 |
GB0711656D0 (en) * | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
DK2714004T3 (da) * | 2011-05-25 | 2024-06-10 | Camurus Ab | Peptidformuleringer med kontrolleret frigivelse |
CA2874367C (en) * | 2012-05-25 | 2020-08-18 | Camurus Ab | Somatostatin receptor agonist formulations |
EP3791861A1 (en) | 2012-07-26 | 2021-03-17 | Camurus AB | Opioid formulations |
EP2823808A1 (en) * | 2013-07-09 | 2015-01-14 | Ipsen Pharma S.A.S. | Pharmaceutical composition for a sustained release of lanreotide |
SG11201603115YA (en) | 2013-10-22 | 2016-05-30 | Prolynx Llc | Conjugates of somatostatin and its analogs |
US10722462B2 (en) | 2014-12-10 | 2020-07-28 | Council Of Scientific And Industrial Research | Discontinuous reverse micellar composition in cubic FD3M phase for sustained release of therapeutic drugs |
EA033590B1 (ru) * | 2014-12-23 | 2019-11-07 | Camurus Ab | Препараты с контролируемым высвобождением |
GB201516554D0 (en) * | 2015-09-18 | 2015-11-04 | Camurus Ab | Controlled-release formulations |
ITUB20160416A1 (it) * | 2016-01-28 | 2017-07-28 | Italfarmaco Spa | Uso di una formulazione a lento rilascio di octreotide per la prevenzione della formazione di seroma |
BR112018069591A2 (pt) * | 2016-03-31 | 2019-04-16 | Sun Pharma Advanced Research Company Limited | gel viscoelástico e método para o controle de níveis de glicose no sangue |
PT3512495T (pt) * | 2016-09-15 | 2023-02-15 | Camurus Ab | Formulações análogas a prostaciclina |
IL295457A (en) | 2016-09-27 | 2022-10-01 | Camurus Ab | Mixtures and formulations containing alkyl ammonium salt edta |
WO2018217926A1 (en) | 2017-05-24 | 2018-11-29 | Vmr Products Llc | Flavor disk |
WO2019182745A1 (en) | 2018-03-19 | 2019-09-26 | Bryn Pharma, LLC | Epinephrine spray formulations |
CA3097927A1 (en) | 2018-05-01 | 2019-11-07 | Chibi, Inc. | Liquid depot for non-invasive sustained delivery of agents to the eye |
CN112423740A (zh) * | 2018-05-01 | 2021-02-26 | 奇比有限公司 | 用于将药物持续递送至视网膜的滴眼剂制剂和方法 |
CN108498849B (zh) * | 2018-05-08 | 2021-04-30 | 武汉百纳礼康生物制药有限公司 | 一种液晶凝胶肝动脉栓塞剂及其制备方法 |
CN109091451B (zh) * | 2018-09-10 | 2021-08-13 | 武汉百纳礼康生物制药有限公司 | 亲水性药物的油相液晶凝胶前体制剂及其制备方法 |
US20220202898A1 (en) | 2019-05-29 | 2022-06-30 | Camurus Ab | Lipid-controlled release compositions |
EP4103587A1 (en) | 2020-02-14 | 2022-12-21 | Immunor AS | Corona virus vaccine |
WO2022093722A1 (en) * | 2020-10-27 | 2022-05-05 | Pts Consulting, Llc | A liquid injectable composition of donepezil |
CN113081954A (zh) * | 2021-05-25 | 2021-07-09 | 南昌大学第二附属医院 | 一种凝胶载药贴剂药物输送系统 |
EP4378452A1 (en) * | 2021-07-27 | 2024-06-05 | Farnex Incorporated | Non-lamellar liquid crystal-forming composition and use thereof |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8206744D0 (sv) | 1982-11-26 | 1982-11-26 | Fluidcarbon International Ab | Preparat for kontrollerad avgivning av substanser |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US5538739A (en) | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
EP0752855B1 (en) * | 1994-03-30 | 1999-06-09 | Gs Development Ab | Use of fatty acid esters as bioadhesive substances |
SE518578C2 (sv) * | 1994-06-15 | 2002-10-29 | Gs Dev Ab | Lipidbaserad komposition |
DK0839525T3 (da) | 1996-10-31 | 2004-11-29 | Takeda Pharmaceutical | Præparat med forlænget frigivelse |
BE1011899A6 (fr) * | 1998-04-30 | 2000-02-01 | Ucb Sa | Compositions pharmaceutiques gelifiables utilisables. |
JP3952617B2 (ja) | 1998-12-11 | 2007-08-01 | 株式会社日立製作所 | 内燃機関の排ガス浄化装置,排ガス浄化方法及び排ガス浄化触媒 |
GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
CA2542708A1 (en) * | 2003-10-24 | 2005-05-06 | University Of Saskatchewan | Dna delivery with gemini cationic surfactants |
WO2006075124A1 (en) * | 2005-01-14 | 2006-07-20 | Camurus Ab | Somatostatin analogue formulations |
US8865021B2 (en) * | 2003-11-07 | 2014-10-21 | Camurus Ab | Compositions of lipids and cationic peptides |
GB0401513D0 (en) | 2004-01-23 | 2004-02-25 | Camurus Ab | Compositions |
EP1713446B1 (en) | 2004-01-23 | 2010-12-01 | Camurus Ab | Ternary non-lamellar lipid compositions |
JP5127449B2 (ja) * | 2004-06-04 | 2013-01-23 | カムルス エービー | 流体デポ製剤 |
KR20070057767A (ko) * | 2004-06-15 | 2007-06-07 | 앤드류 셴 천 | 인지질 조성물 및 이의 제조 및 사용 방법 |
WO2006075123A1 (en) | 2005-01-14 | 2006-07-20 | Camurus Ab | Topical bioadhesive formulations |
KR101245022B1 (ko) | 2005-01-21 | 2013-03-19 | 카무러스 에이비 | 약제학적 지질 조성물 |
CA2609810C (en) | 2005-06-06 | 2012-05-22 | Camurus Ab | Glp-1 analogue formulations |
GB0711656D0 (en) | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
GB0716385D0 (en) * | 2007-08-22 | 2007-10-03 | Camurus Ab | Formulations |
-
2012
- 2012-11-28 JP JP2014545179A patent/JP6081480B2/ja active Active
- 2012-11-28 EP EP12791208.7A patent/EP2787974B1/en active Active
- 2012-11-28 KR KR1020147018578A patent/KR20140105527A/ko not_active Application Discontinuation
- 2012-11-28 AU AU2012348640A patent/AU2012348640B2/en active Active
- 2012-11-28 ES ES12791208.7T patent/ES2629188T3/es active Active
- 2012-11-28 EA EA201491005A patent/EA027924B1/ru not_active IP Right Cessation
- 2012-11-28 BR BR112014013691A patent/BR112014013691A2/pt not_active Application Discontinuation
- 2012-11-28 MX MX2014006624A patent/MX350929B/es active IP Right Grant
- 2012-11-28 US US14/362,517 patent/US9585959B2/en active Active
- 2012-11-28 CA CA2858227A patent/CA2858227C/en active Active
- 2012-11-28 WO PCT/EP2012/073841 patent/WO2013083459A1/en active Application Filing
- 2012-11-28 CN CN201280066168.1A patent/CN104093399B/zh active Active
- 2012-11-28 DK DK12791490.1T patent/DK2787975T3/da active
- 2012-11-28 DK DK12791208.7T patent/DK2787974T3/en active
- 2012-11-28 EP EP12791490.1A patent/EP2787975B1/en active Active
- 2012-11-28 EA EA201490921A patent/EA028040B1/ru not_active IP Right Cessation
- 2012-11-28 CN CN201280066173.2A patent/CN104105479B/zh active Active
- 2012-11-28 JP JP2014545177A patent/JP6081479B2/ja active Active
- 2012-11-28 ES ES12791490.1T patent/ES2645345T3/es active Active
- 2012-11-28 AU AU2012348641A patent/AU2012348641B2/en active Active
- 2012-11-28 SI SI201230991T patent/SI2787974T1/sl unknown
- 2012-11-28 BR BR112014013693-9A patent/BR112014013693B1/pt active IP Right Grant
- 2012-11-28 MX MX2014006625A patent/MX352024B/es active IP Right Grant
- 2012-11-28 PE PE2014000875A patent/PE20141297A1/es not_active Application Discontinuation
- 2012-11-28 SG SG11201402673YA patent/SG11201402673YA/en unknown
- 2012-11-28 PL PL12791490T patent/PL2787975T3/pl unknown
- 2012-11-28 US US14/362,542 patent/US9555118B2/en active Active
- 2012-11-28 KR KR1020147018186A patent/KR101979051B1/ko active IP Right Grant
- 2012-11-28 CA CA2857982A patent/CA2857982A1/en not_active Abandoned
- 2012-11-28 WO PCT/EP2012/073843 patent/WO2013083460A1/en active Application Filing
-
2014
- 2014-05-23 ZA ZA2014/03793A patent/ZA201403793B/en unknown
- 2014-05-26 IL IL23278914A patent/IL232789B/en active IP Right Grant
- 2014-06-05 CL CL2014001472A patent/CL2014001472A1/es unknown
- 2014-06-05 IL IL232967A patent/IL232967A0/en unknown
- 2014-07-02 CO CO14142113A patent/CO7000746A2/es unknown
-
2015
- 2015-03-04 HK HK15102185.4A patent/HK1201722A1/xx unknown
- 2015-03-06 HK HK15102298.8A patent/HK1201735A1/xx unknown
-
2017
- 2017-06-23 HR HRP20170954TT patent/HRP20170954T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014006624A (es) | Formulaciones peptidicas robustas de liberación controlada. | |
MX361716B (es) | Formulaciones peptidicas de liberacion controlada. | |
MX2018003333A (es) | Formulaciones de liberacion controlada. | |
ATE501710T1 (de) | Somatostatin-analog-formulierungen | |
DE602005008247D1 (de) | Flüssige depotformulierungen | |
AR083016A1 (es) | Formulaciones liquidas para la agricultura con una mejor estabilidad | |
PE20130230A1 (es) | Derivados de carboxamidas n-azabiciclicas y su preparacion | |
EA201490489A1 (ru) | Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7 | |
CO6251200A2 (es) | Metodo para modular la tasa de liberacion de ingredientes activos microencapsulados usado paa la proteccion de cultivos | |
EA201291108A1 (ru) | Фармацевтические композиции в виде эмульсии с низким содержанием масла, содержащие прогестоген | |
BR112012006686B8 (pt) | compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa | |
PH12014502614A1 (en) | Somatostatin receptor agonist formulations | |
AR081535A1 (es) | Formulaciones liquidas oleosas estables listas para usar, su preparacion y uso | |
IL251413B2 (en) | Composition of injectable buprenorphine | |
CL2011000148A1 (es) | Compuestos derivados de piperidina puenteada tipo quinoxalina, de accion moduladora del receptor orl-1; composicion farmaceutica que los comrende; procedimiento de preparacion de la composicion; kit farmaceutico; y uso de los compuestos para el tratamiento del dolor. | |
BRPI0714761B8 (pt) | formulações compreendendo compostos cíclicos | |
HRP20210068T1 (hr) | Opioidne formulacije | |
BR112012015433B8 (pt) | composição farmacêutica substancialmente anidra para aplicação cutânea | |
EA201791166A1 (ru) | Препараты с контролируемым высвобождением | |
SA521430973B1 (ar) | صيغ علاجية ثابتة في مذيبات قطبية غير بروتونية وطرق لتصنيعها | |
BR112015015476A8 (pt) | uso de compostos químicos capazes de inibir a ação tóxica das esfingomielinases d do veneno de aranhas loxosceles e composição farmacêutica compreendendo os referidos compostos | |
NZ730521B2 (en) | Injectable buprenorphine formulation | |
RU2012127261A (ru) | Фармацевтическая композиция хондропротекторов для трансдермального применения | |
TH161414B (th) | สูตรผสมโอปิออยด์ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |